Cargando…
Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study
BACKGROUND: Antibiotics are considered to be among the most frequent causes of drug-related acute liver injury (ALI). Although many ALIs have mild and reversible clinical outcomes, there is substantial risk of severe reactions leading to acute liver failure, need for liver transplant, and death. Rec...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258930/ https://www.ncbi.nlm.nih.gov/pubmed/34537834 http://dx.doi.org/10.1093/cid/ciab825 |
_version_ | 1784741660179038208 |
---|---|
author | Nibell, Olof Svanström, Henrik Inghammar, Malin |
author_facet | Nibell, Olof Svanström, Henrik Inghammar, Malin |
author_sort | Nibell, Olof |
collection | PubMed |
description | BACKGROUND: Antibiotics are considered to be among the most frequent causes of drug-related acute liver injury (ALI). Although many ALIs have mild and reversible clinical outcomes, there is substantial risk of severe reactions leading to acute liver failure, need for liver transplant, and death. Recent studies have raised concerns of hepatotoxic potential related to the use of fluoroquinolones. METHODS: This study examined the risk of ALI associated with oral fluoroquinolone treatment compared with amoxicillin (419 930 courses, propensity score matched 1:1). The information on drug use was collected from a national, registry-based cohort derived from all Swedish adults aged 40–85 years. RESULTS: During a follow-up period of 60 days, users of oral fluoroquinolones had a >2-fold risk of ALI compared to users of amoxicillin (hazard ratio, 2.32 [95% confidence interval {CI}, 1.01–5.35). The adjusted absolute risk difference for use of fluoroquinolones as compared to amoxicillin was 4.94 (95% CI, .04–16.3) per 1 million episodes. CONCLUSIONS: In this propensity score–matched study, fluoroquinolone treatment was associated with an increased risk of ALI in the first 2 months after starting treatment. |
format | Online Article Text |
id | pubmed-9258930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92589302022-07-07 Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study Nibell, Olof Svanström, Henrik Inghammar, Malin Clin Infect Dis Major Articles and Commentaries BACKGROUND: Antibiotics are considered to be among the most frequent causes of drug-related acute liver injury (ALI). Although many ALIs have mild and reversible clinical outcomes, there is substantial risk of severe reactions leading to acute liver failure, need for liver transplant, and death. Recent studies have raised concerns of hepatotoxic potential related to the use of fluoroquinolones. METHODS: This study examined the risk of ALI associated with oral fluoroquinolone treatment compared with amoxicillin (419 930 courses, propensity score matched 1:1). The information on drug use was collected from a national, registry-based cohort derived from all Swedish adults aged 40–85 years. RESULTS: During a follow-up period of 60 days, users of oral fluoroquinolones had a >2-fold risk of ALI compared to users of amoxicillin (hazard ratio, 2.32 [95% confidence interval {CI}, 1.01–5.35). The adjusted absolute risk difference for use of fluoroquinolones as compared to amoxicillin was 4.94 (95% CI, .04–16.3) per 1 million episodes. CONCLUSIONS: In this propensity score–matched study, fluoroquinolone treatment was associated with an increased risk of ALI in the first 2 months after starting treatment. Oxford University Press 2021-09-19 /pmc/articles/PMC9258930/ /pubmed/34537834 http://dx.doi.org/10.1093/cid/ciab825 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Articles and Commentaries Nibell, Olof Svanström, Henrik Inghammar, Malin Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study |
title | Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study |
title_full | Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study |
title_fullStr | Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study |
title_full_unstemmed | Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study |
title_short | Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study |
title_sort | oral fluoroquinolone use and the risk of acute liver injury: a nationwide cohort study |
topic | Major Articles and Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258930/ https://www.ncbi.nlm.nih.gov/pubmed/34537834 http://dx.doi.org/10.1093/cid/ciab825 |
work_keys_str_mv | AT nibellolof oralfluoroquinoloneuseandtheriskofacuteliverinjuryanationwidecohortstudy AT svanstromhenrik oralfluoroquinoloneuseandtheriskofacuteliverinjuryanationwidecohortstudy AT inghammarmalin oralfluoroquinoloneuseandtheriskofacuteliverinjuryanationwidecohortstudy |